Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-molecular-weight heparin plus insulin versus insulin alone for acute triglyceride-lowering therapy in hypertriglyceridemic pancreatitis
ChiCTR1900023640Phase 4Completed
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium and human insulin in Hypertriglyceridaemic Pancreatitis (HTGP), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Composite of new-onset organ failure and mortality. Started Jun 2019; status: completed.
02
Drugs
low molecular weight heparin calciumhuman insulin
03
Conditions
Hypertriglyceridaemic Pancreatitis (HTGP)
Beyond the preview
Go deeper on ChiCTR1900023640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023640.